

Renegotiated licensing agreement and information about the first day of trade

The licensing agreement with CombiGene has recently been renegotiated. The revised agreement is now finalized and statements concerning CombiGene's entitlement to withdrawal have been reformulated. Levels of remuneration to Panion in the event of a withdrawal have also been adjusted.

Since the licensing agreement is of material significance for Panion's business operation, it has not been possible to complete the application for listing on AktieTorget. With the finalization of the agreement, Panion hopes to be able to announce a date for the start of trading on AktieTorget within the very near future.

For further information, please contact:

Anja E. H. Holm, VD | +45-22 94 66 00
anja.holm@panion-animalhealth.com

In June 2015 CombiGene formed a wholly owned subsidiary, then called CombiGene Vet AB, and in April 2016 the decision was taken to distribute the subsidiary to CombiGene's shareholders with the aim of listing the company. The company, which has been renamed Panion Animal Health AB, will use CombiGene's discoveries to develop a treatment for canine epilepsy. Panion aims at inlicensing or acquiring other veterinary medicine projects or products.

Panion Animal Health AB

Frykholmogatan 11, 281 31 Hässleholm, Sweden
info@panion-animalhealth.com

[linkedin.com/company/panion-animalhealth](https://www.linkedin.com/company/panion-animalhealth) 
twitter.com/panionanihealth 
panion-animalhealth.com/newsletter 
panion-animalhealth.com 